Examine the institutional architecture — ICMR, AYUSH Ministry, WHO-GCTM — for research and integration of traditional medicine in India.

India's traditional medicine ecosystem rests on a three-tier architecture: a policy ministry (AYUSH), a research council (ICMR), and a global standard-setting node (WHO-GCTM). Together they seek evidence-based mainstreaming, though coordination gaps persist.

Ministry of AYUSH — the policy and delivery arm

• Nodal ministry for Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy, carved out as a separate ministry to give traditional systems administrative identity [1].
• Implements the National AYUSH Mission (2014), a centrally sponsored scheme co-locating AYUSH services in primary health facilities, supporting drug quality control and medicinal plant cultivation [1].
• Weakness: policy and delivery capacity outpaces its independent research validation ability, making it dependent on partners.

ICMR — the scientific validation arm

• Apex biomedical research body under the Health Ministry, supplying the clinical-trial rigour AYUSH claims require.
• Its dedicated ICMR-National Institute of Traditional Medicine (NITM), Belagavi scientifically evaluates herbal drugs of both codified and non-codified systems and studies diseases of regional importance [2].
• Continuity is notable: WHO-ICMR collaboration on Ayurvedic research dates to the 1970s, when a joint team examined Ayurvedic treatment of rheumatism with the Ayurvedic Trust, Coimbatore.

WHO-GCTM — the global interface

• Established by a 2022 WHO-India agreement at Jamnagar, Gujarat, the first and only WHO outposted global centre for traditional medicine, with an interim office at ITRA [3].
• Works on evidence and learning, data and analytics, sustainability and equity, and innovation — helping countries integrate and regulate traditional medicine safely [3].
• India leveraged it for health diplomacy: the Second WHO Global Summit on Traditional Medicine, New Delhi (December 2025) advanced the WHO global traditional medicine strategy to 2034 [4].

The architecture is thus complementary — AYUSH governs, ICMR validates, GCTM globalises — but its effectiveness hinges on institutionalised inter-ministerial coordination and stronger regulatory capacity for drug quality. Deepening ICMR-AYUSH joint trial protocols and anchoring outcomes in GCTM's evidence framework would convert India's civilisational advantage into credible, universally accepted healthcare, advancing SDG-3.